The transjugular intrahepatic portosystemic shunt for the management of cirrhotic refractory ascites

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 3, Issue 7, 2006, Pages 380-389

  Garcia Tsao, Guadalupe ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ascites; Large volume paracentesis; Refractory ascites; TIPS; Transjugular

Indexed keywords

ALBUMIN; BILIRUBIN; CREATININE; DIURETIC AGENT; LACTITOL; POLITEF; RIFAXIMIN;

AGING; ASCITES; BILIRUBIN BLOOD LEVEL; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; CORRELATION FUNCTION; CREATININE BLOOD LEVEL; DISEASE PREDISPOSITION; DISEASE SEVERITY; ETHNOLOGY; EVIDENCE BASED MEDICINE; HEMODYNAMICS; HEMOPERITONEUM; HEPATIC ENCEPHALOPATHY; HOSPITALIZATION; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION; LIVER SINUSOID; LIVER TRANSPLANTATION; MEDLINE; META ANALYSIS; MORTALITY; PARACENTESIS; PLASMA RENIN ACTIVITY; PORTOSYSTEMIC ANASTOMOSIS; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; REOPERATION; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SODIUM RETENTION; SODIUM URINE LEVEL; STENT; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; VARICOSIS; VASCULAR RESISTANCE; VASODILATATION;

ASCITES; BILIRUBIN; HEMODYNAMIC PROCESSES; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER CIRRHOSIS; PARACENTESIS; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; RANDOMIZED CONTROLLED TRIALS; SODIUM; STENTS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33745767750     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0523     Document Type: Review

References (57)

1. Gines P et al. (1987) Compensated cirrhosis: Natural history and prognosis. Hepatology 7: 122-128
2. D'Amico G et al. (1986) Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 31: 468-475
3. Loureiro-Silva MR et al. (2003) Deficit in nitric oxide production in cirrhotic rat livers is located in the sinusoidal and postsinusoidal areas. Am J Physiol Gastrointest Liver Physiol 284: G567-G574
4. Rector WG (1986) Portal hypertension: A permissive factor only in the development of ascites and variceal bleeding. Liver 6: 221-226
5. Morali GA et al. (1992) Is sinusoidal portal hypertension a necessary factor for the development of hepatic ascites? J Hepatol 16: 249-250
6. Abraldes JG et al. (2003) Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 37: 902-908
7. Casado M et al. (1998) Clinical events after transjugular intrahepatic portosystemic shunt: Correlation with hemodynamic findings. Gastroenterology 114: 1296-1303
8. Hoefs JC (1983) Serum protein concentration and portal pressure determine the ascitic fluid protein concentration in patients with chronic liver disease. J Lab Clin Med 102: 260-273
9. Schrier RW et al. (1988) Peripheral arterial vasodilation hypothesis - a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8: 1151-1157
10. Martin PY et al. (1998) Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 339: 533-541
11. Martin PY et al. (1998) Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites. J Clin Invest 101: 235-242
12. Arroyo V et al. (1996) Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 23: 164-176
13. Salerno F et al. (1993) Survival and prognostic factors of cirrhotic patients with ascites: A study of 134 outpatients. Am J Gastroenterol 88: 514-519
14. Castells A et al. (1994) Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: A retrospective study. Hepatology 20: 584-591
15. Orloff MJ et al. (1997) Experimental, clinical, and metabolic results of side-to-side portacaval shunt for intractable cirrhotic ascites. J Am Coll Surg 183: 557-570
16. Voorhees ABJ et al. (1970) Portasystemic shunting procedures for portal hypertension. Twenty-six year experience in adults with cirrhosis of the liver. Am J Surg 119: 501-505
17. Wong F et al. (1995) Transjugular intrahepatic portosystemic stent shunt: Effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann Intern Med 122: 816-822
18. Quiroga J et al. (1995) Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: Effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology 21: 986-994
19. Wong F et al. (1997) The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt. Gastroenterology 112: 899-907
20. Wong W et al. (1999) Long-term renal sodium handling in patients with cirrhosis treated with transjugular intrahepatic portosystemic shunts for refractory ascites. Am J Med 106: 315-322
21. Gerbes AL et al. (1998) Renal effects of transjugular intrahepatic portosystemic shunt in cirrhosis: Comparison of patients with ascites, with refractory ascites or without ascites. Hepatology 28: 683-688
22. Somberg KA et al. (1995) Transjugular intrahepatic portosystemic shunts for refractory ascites: Assessment of clinical and hormonal response and renal function. Hepatology 21: 709-716
23. Lebrec D et al. (1996) Transjugular intrahepatic portosystemic shunts: comparison with paracentesis in patients with cirrhosis and refractory ascites: A randomized trial. J Hepatol 25: 135-144
24. Garcia-Tsao G (2005) Transjugular intrahepatic portosystemic shunt in the management of refractory ascites. Semin Interventional Rad 22: 278-286
25. Russo MW et al. (2003) Transjugular intrahepatic portosystemic shunt for refractory ascites: An analysis of the literature on efficacy, morbidity, and mortality. Am J Gastroenterol 98: 2521-2527
26. Sanyal AJ et al. (1994) Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: Results of a prospective controlled study. Hepatology 20: 46-54
27. Nolte W et al. (1998) Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Clinical, laboratory, psychometric, and electroencephalographic investigations. Hepatology 28: 1215-1225
28. Riggio O et al. (2005) Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: A randomized controlled study. J Hepatol 42: 674-679
29. Riggio O et al. (1996) Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors. Dig Dis Sci 41: 578-584
30. Hassoun Z et al. (2001) Relationship between pre-TIPS liver perfusion by the portal vein and the incidence of post-TIPS chronic hepatic encephalopathy. Am J Gastroenterol 96: 1205-1209
31. Bureau C et al. (2004) Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: Results of a randomized study. Gastroenterology 126: 469-475
32. Boyer TD and Haskal ZJ (2005) The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 41: 386-400
33. Moore KP et al. (2003) The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. Hepatology 38: 258-266
34. Gines A et al. (1996) Randomized trial comparing albumin, dextran-70 and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 111: 1002-1010
35. Ruiz del Arbol L et al. (1997) Paracentesis-induced circulatory dysfunction: Mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 113: 579-586
36. Sola-Vera J et al. (2003) Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 37: 1147-1153
37. Rossle M et al. (2000) A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 342: 1701-1707
38. Gines P et al. (2002) Transjugular intrahepatic portosystemic shunting versus repeated paracentesis plus intravenous albumin for refractory ascites in cirrhosis: A multicenter randomized comparative study. Gastroenterology 123: 1839-1847
39. Sanyal AJ et al. (2003) The North American Study for the Treatment of Refractory Ascites. Gastroenterology 124: 634-641
40. Salerno F et al. (2004) Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology 40: 629-635
41. Saab S et al. (2004) TIPS versus paracentesis for cirrhotic patients with refractory ascites. The Cochrane Database of Systematic Reviews, Issue 3, Art. No CD004889
42. Deltenre P et al. (2005) Transjugular intrahepatic portosystemic shunt in refractory ascites: A meta-analysis. Liver Int 25: 349-356
43. D'Amico G et al. (2005) Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: A meta-analysis. Gastroenterology 129: 1282-1293
44. Albillos A et al. (2005) A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J Hepatol 43: 990-996
45. Luca A et al. (1999) TIPS for prevention of recurrent bleeding in patients with cirrhosis: Meta-analysis of randomized clinical trials. Radiology 212: 411-421
46. Campbell MS et al. (2005) Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy. Hepatology 42: 635-640
47. Chalasani N et al. (2000) Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting. Gastroenterology 118: 138-144
48. Malinchoc M et al. (2000) A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31: 864-871
49. Russo MW et al. (2002) Predictors of mortality and stenosis after transjugular intrahepatic portosystemic shunt. Liver Transpl 8: 271-277
50. Angermayr B et al. (2003) Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut 52: 879-885
51. Thuluvath PJ et al. (2003) TIPS for management of refractory ascites: response and survival are both unpredictable. Dig Dis Sci 48: 542-550
52. Alessandria C et al. (2004) Application of the model for end-stage liver disease score for transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory ascites and renal impairment. Eur J Gastroenterol Hepatol 16: 607-612
53. ter Borg PC et al. (2004) Transjugular intrahepatic portosystemic shunts: Long-term patency and clinical results in a patient cohort observed for 3-9 years. Radiology 231: 537-545
54. Membreno F et al. (2005) Differences in long-term survival after transjugular intrahepatic portosystemic shunt for refractory ascites and variceall bleed. J Gastroenterol Hepatol 20: 474-481
55. D'Amico G et al. (2006) Natural history and prognostic indicators of survival in cirrhosis. A systematic review of 118 studies. J Hepatol 44: 217-231
56. Gerbes AL and Gulberg V (2005) Benefit of TIPS for patients with refractory or recidivant ascites: Serum bilirubin may make the difference. Hepatology 41: 217
57. Ferrel H et al. (1993) Refractory ascites: Early experience with transjugular intrahepatic portosystemic shunt. Radiology 189: 795-801